ST. LOUIS–(BUSINESS WIRE)–Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the appointment of Vince Wong as Chief Commercial Officer.

Mr. Wong brings almost 18 years of experience from Roche Diagnostics, where he served in senior leadership roles in product marketing, sales, strategy, business development, market access, and communications. Most recently, Mr. Wong served as Roche Diagnostics’ Vice President of Sales, Point of Care Diagnostics and as Vice President / General Manager of Physician Office and Specialty Diagnostics, managing >$600M in sales. At Roche, Mr. Wong led teams serving physician groups, hospital systems, patients, biopharma, retail pharmacies, and payors in the areas of Diabetes, Oncology, Infectious Disease, and Women’s Health.

“Vince is joining us at an exciting, pivotal moment and is going to be a great asset to our team at Geneoscopy,” said Andrew Barnell, Geneoscopy’s CEO. “The breadth of Vince’s experience in commercializing innovative diagnostics globally will serve Geneoscopy well as we prepare to launch products to address unmet needs in the gastrointestinal health space.”

“The Geneoscopy team has developed a platform that will have a meaningful impact on patient outcomes,” said Mr. Wong. “Geneoscopy’s vision and mission will enable clinicians to practice precision medicine in an area that urgently needs such an approach. I am excited to be a part of this talented team to deliver our first product in colorectal cancer screening to clinicians, patients, and payors.”

About Geneoscopy Inc.

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest that the diagnostic can detect these lesions at a higher rate than all existing noninvasive screening tests.

Web |

Twitter |

Facebook |

LinkedIn |

Geneoscopy Inc. Forward-Looking Statements

The information contained in this release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, and as such constitute forward-looking statements. These forward-looking statements are based upon the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Although the Company believes that its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved and the actual results may differ substantially from the projected results.